Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT04046107 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Temporarily closed to enrollment

Conditions

Hepatitis B Virus

Interventions

BIOLOGICAL: Cemiplimab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]